EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Fatty acid Sources: 4

Evening primrose oil Oenothera biennis L.

Also called: EPO, evening primrose

An oil from the seeds of the evening primrose plant. It contains omega-6 fatty acids, including gamma-linolenic acid (GLA), and is sold as a dietary supplement.

Category
Fatty acid
Forms
Seed oil
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. A 2013 Cochrane review included 27 RCTs (1,596 participants) of oral evening primrose oil or borage oil for eczema; 19 assessed evening primrose oil, and meta-analyses of evening primrose oil versus placebo pooled 7 and 8 trials. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied3 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Evening primrose oil does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Evening primrose oil, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Eczema (atopic dermatitis), oral useXA Cochrane review of 27 studies (1,596 participants; 19 on evening primrose oil) found no benefit over placebo on global eczema symptoms rated by participants or doctors. [3]
Breast painCNCCIH states it is probably no more effective than a placebo. [1]
Starting laborCStudies of oral and vaginal use to help start labor have had inconsistent results. [1]
Rheumatoid arthritis, premenstrual syndrome, menopause symptomsCNCCIH states there is not enough evidence for these conditions. [1]

Main constituents: Omega-6 fatty acids, including gamma-linolenic acid (GLA) [1]; GLA makes up about 10% of the oil [2]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: evening primrose oil may be safe during pregnancy and while breastfeeding, but the evidence is not conclusive …

    3 statements in the profile.

    Details and sources
  • Interactions with medicines
    3 listed

    Anticoagulants and antiplatelet drugs; Antiretroviral drugs; Blood pressure medicines

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum (EMA/HMPC/753041/2017, Revision 1, 5 June 2018), traditional use for …

    Details and sources
  • Probably safe for most adults when taken orally; less is known about children. Most common side effects are gastrointestinal, such as abdominal pain, nausea or diarrhea. [1]
  • Other reported effects: indigestion, softening of stools and headaches; a case of lipoid pneumonia after chronic use. [2]
  • When used to shorten gestation and labor, reported problems include more prolonged membrane rupture, oxytocin augmentation, arrest of descent and vacuum extraction; petechiae and bruising occurred in a newborn whose mother used it. [2]
  • Pregnancy: NCCIH says it may be safe during pregnancy, but the evidence is not conclusive and long-term safety has not been established. [1]
  • Pregnancy: MSK says pregnant women should not take it because of increased risk of pregnancy complications. Use caution with hormone-sensitive cancers, because some products contain phytoestrogens. [2]
  • Breastfeeding: it raises GLA levels in breast milk; no harm to infants has been reported. [1]
Interactions

Interactions

Evening primrose oil
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Evening primrose oil
WithWhat happens
Anticoagulants and antiplatelet drugsMay have additive effects and increase bleeding risk. [2]
Antiretroviral drugsEvening primrose oil was reported to significantly increase levels of antiretroviral drugs. [2]
Blood pressure medicinesNo interactions are reported, but the oil may raise systolic and diastolic blood pressure. [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Regulation

Regulatory status

  • US: sold as a dietary supplement; supplements are not FDA-approved before sale. [1]
  • EU: European Union herbal monograph (Oenotherae oleum) based on traditional use for relief of itching in short-term and long-term dry skin conditions. [4]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Gamma-linolenic acid (GLA), an omega-6 fatty acid; the oil is about 10% GLA Fatty acids and lipids (omega-6 fatty acid) [P6]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming evening primrose (Oenothera biennis) (earliest NDI 47 submitted 1999-02-05; most recent NDI 82 submitted 2000-04-27). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of evening primrose oil was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P2]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of evening primrose oil (checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Anticoagulants and antiplatelet drugs: May have additive effects and increase bleeding risk; in a small human study of several months of GLA from evening primrose oil, bleeding time increased significantly in 9 of 12 patients. [P6]
  • Antiretroviral drugs: In humans, evening primrose oil significantly increased levels of antiretroviral drugs and may increase the risk of adverse effects. [P6]
  • Blood pressure medicines: No interactions reported, but a large population-based study identified evening primrose oil among supplements that may raise systolic and diastolic blood pressure. [P6]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • Of 69 coconut, safflower, evening primrose and linseed oils sold in São Paulo, 43% had fatty acid profiles that did not match their labels, with a higher incidence of adulteration among evening primrose oils; adulterated samples contributed more to exceedances of EU PAH limits (Silva et al., 2018). [P7]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
  • Fatty acid profile to confirm oil identity — Fatty acid profiles revealed adulteration of evening primrose oils in a market survey. [P7]
  • Polycyclic aromatic hydrocarbons (benzo[a]pyrene and the sum of 4 PAHs) — PAHs were detected in 96% of 69 vegetable oil samples; EU limits were exceeded for benzo[a]pyrene in 12% and for total 4 PAHs in 28%. [P7]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum (EMA/HMPC/753041/2017, Revision 1, 5 June 2018), traditional use for itching in acute and chronic dry skin conditions, adolescents, adults and elderly: single dose 2–3 g, daily dose 4–6 g, oral. [P8]

Pregnancy and breastfeeding

  • NCCIH: evening primrose oil may be safe during pregnancy and while breastfeeding, but the evidence is not conclusive; the long-term safety of using it to try to start labor has not been established. Use while breastfeeding increases GLA in breast milk without reported harm to the infant. [P5]
  • MSK: pregnant women should not take evening primrose oil because of increased risk of pregnancy complications. [P6]
  • EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use is not recommended. [P8]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. NCCIH. Evening Primrose Oil (Last Updated: November 2024), 2024-11. nccih.nih.gov
  6. Memorial Sloan Kettering Cancer Center. About Herbs: Evening Primrose Oil (last updated February 16, 2022), 2022-02-16. mskcc.org
  7. Silva SAD, et al. Polycyclic aromatic hydrocarbons content and fatty acids profile in coconut, safflower, evening primrose and linseed oils. Food Chem 2018;245:798-805 (PMID 29287444), 2018-04-15. pubmed.ncbi.nlm.nih.gov
  8. European Medicines Agency, HMPC. European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum, EMA/HMPC/753041/2017 (Final, Revision 1, 5 June 2018), 2018-06-05. ema.europa.eu
Sources

Sources

  1. NCCIH. Evening Primrose Oil (last updated November 2024), 2024-11. nccih.nih.gov
  2. Memorial Sloan Kettering Cancer Center. About Herbs: Evening Primrose Oil (last updated February 16, 2022), 2022-02-16. mskcc.org
  3. Bamford JTM, Ray S, Musekiwa A, et al. Oral evening primrose oil and borage oil for eczema. Cochrane Database of Systematic Reviews 2013, Issue 4, CD004416, 2013-04-30. cochrane.org
  4. European Medicines Agency. Oenotherae oleum: herbal medicinal product (monograph Rev. 1, 10/10/2018; addendum 11/02/2026), 2026-02-11. ema.europa.eu
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in fatty acid: Algal oil (DHA and EPA) · Arachidonic acid · Argan oil · Conjugated linoleic acid (CLA) · GLA oils (borage and blackcurrant seed oil) · Krill oil · Linoleic acid · MCT oil (medium-chain triglycerides) · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.